Gross profit (FY, 2016)1.3 M

Gross profit margin (FY, 2016), %53%

Net income (FY, 2016)-3.3 M

EBITDA (FY, 2016)-3.6 M

EBIT (FY, 2016)-3.7 M

Cash, 31-Dec-20162.3 M

## Founding Date | 2009 |

## Total Funding | $17.9 m |

## Latest funding size | $13.50 m |

## Time since last funding | 3 years ago |

## Investors | Amadeus Capital Partners, Smedvig Capital, Octopus Ventures |

Antidote's latest funding round in February 2015 was reported to be $13.5 m. In total, Antidote has raised $17.9 m

GBP | FY, 2015 | FY, 2016 |
---|---|---|

## Revenue | 2.2 m | 2.4 m |

## Cost of goods sold | 912.3 k | 1.1 m |

## Gross profit | 1.3 m | 1.3 m |

| 59% | 53% |

## Operating expense total | 3.8 m | 4.9 m |

## EBITDA | (2.5 m) | (3.6 m) |

| (110%) | (151%) |

## EBIT | (2.5 m) | (3.7 m) |

| (110%) | (152%) |

## Pre tax profit | (2.5 m) | (3.7 m) |

## Income tax expense | 218.5 k | 375.3 k |

## Net Income | (2.2 m) | (3.3 m) |

GBP | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|---|

## Cash | 284.3 k | 1.9 m | 147.5 k | 1.3 m | 2.3 m |

## Accounts Receivable | 73.1 k | 211.4 k | 504.2 k | 647.1 k | 967.5 k |

## Current Assets | 357.4 k | 2.1 m | 651.8 k | 2.2 m | 3.7 m |

## PP&E | 1.5 k | 6.7 k | 14.9 k | 85.5 k | 77 k |

## Total Assets | 388.1 k | 2.1 m | 666.7 k | 2.4 m | 3.9 m |

## Accounts Payable | 23.9 k | 61.6 k | 1 m | 226.3 k | 77.5 k |

## Current Liabilities | 23.9 k | 61.6 k | 1 m | 442.1 k | 638.8 k |

## Non-Current Liabilities | 54 k | 132.5 k | |||

## Total Liabilities | 23.9 k | 61.6 k | 1 m | 496 k | 771.4 k |

## Additional Paid-in Capital | 43 k | 45.1 k | 44.3 k | 45 k | 45.9 k |

## Retained Earnings | (2.2 m) | (3.3 m) | |||

## Total Equity | 364.2 k | 2.1 m | (363.4 k) | 1.9 m | 3.1 m |

## Financial Leverage | 1.1 x | 1 x | -1.8 x | 1.3 x | 1.2 x |

GBP | FY, 2015 | FY, 2016 |
---|---|---|

## Net Income | (2.2 m) | (3.3 m) |

GBP | Y, 2016 |
---|---|

## Revenue/Employee | 46.2 k |

## Financial Leverage | 1.2 x |

Report incorrect company information